MMP7
Matrilysin
As of the edition of 20 October 2026, MMP7 (matrilysin, UniProt P09237) has 2 drugs tested at it and 8 companies on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P09237
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 16
- Disease areas
- Infections; Skin and connective tissue; Lungs and airways; Urinary and reproductive; Cancer; Heart and blood vessels; Immune system; Inherited and neonatal
- Registered trials of its drugs
- 232
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Doxycycline anhydrous | Marketed | Phase 4 | none listed |
| Marimastat | Active | Phase 3 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Engaged | 7 |
| Total on the list | 8 |
| Company | Route |
|---|---|
| Pfizer | Route B |
The other 7 companies at MMP7
In the product8 companies in all; 7 are not named here, and no score is.
See the 8 companies at MMP7, ranked, with the facts behind eachRequest access. Nothing is shown until you do.